{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:44Z","timestamp":1791921524168,"version":"4.3.4"},"reference-count":48,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["HHSN272201700039I"],"award-info":[{"award-number":["HHSN272201700039I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies. This combination of weakened-host defense, with limited antifungal treatment options, and the opportunism of environmental molds renders patients at risk and especially vulnerable to invasive mold infections such as Aspergillus and members of the Order Mucorales. Currently, available antifungal drugs such as azoles and echinocandins, as well as combinations of the same, offer some degree of efficacy in the prevention and treatment of invasive mold infections, but their use is often limited by drug resistance mechanisms, toxicity, drug-drug interactions, and the relative paucity of oral treatment options. Clearly, there is a need for agents that are of a new class that provides adequate tissue penetration, can be administered orally, and have broad-spectrum efficacy against fungal infections, including those caused by invasive mold organisms. Ibrexafungerp, an orally bioavailable glucan synthase inhibitor, is the first in a new class of triterpenoid antifungals and shares a similar target to the well-established echinocandins. Ibrexafungerp has a very favorable pharmacokinetic profile for the treatment of fungal infections with excellent tissue penetration in organs targeted by molds, such as the lungs, liver, and skin. Ibrexafungerp has demonstrated in vitro activity against Aspergillus spp. as well as efficacy in animal models of invasive aspergillosis and mucormycosis. Furthermore, ibrexafungerp is approved for use in the USA for the treatment of women with vulvovaginal candidiasis. Ibrexafungerp is currently being evaluated in clinical trials as monotherapy or in combination with other antifungals for treating invasive fungal infections caused by yeasts and molds. Thus, ibrexafungerp offers promise as a new addition to the clinician\u2019s armamentarium against these difficult-to-treat infections.<\/jats:p>","DOI":"10.3390\/jof8111121","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T23:50:28Z","timestamp":1666741828000},"page":"1121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections"],"prefix":"10.3390","volume":"8","author":[{"given":"David A.","family":"Angulo","sequence":"first","affiliation":[{"name":"SCYNEXIS, Inc., Jersey City, NJ 07302, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-6040","authenticated-orcid":false,"given":"Riina","family":"Rautemaa-Richardson","sequence":"additional","affiliation":[{"name":"Mycology Reference Centre Manchester, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK"},{"name":"Department of Infectious Diseases, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4405","authenticated-orcid":false,"given":"Ana","family":"Alastruey-Izquierdo","sequence":"additional","affiliation":[{"name":"Mycology Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-8530","authenticated-orcid":false,"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA"},{"name":"The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"King","sequence":"additional","affiliation":[{"name":"SCYNEXIS, Inc., Jersey City, NJ 07302, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi E.","family":"Azie","sequence":"additional","affiliation":[{"name":"SCYNEXIS, Inc., Jersey City, NJ 07302, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center for Innovative Therapeutics and Diagnostics, Richmond, VA 23223, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.12688\/f1000research.28327.1","article-title":"Novel antifungal agents in clinical trials","volume":"10","author":"Jacobs","year":"2021","journal-title":"F1000Research"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/clinchem\/hvab217","article-title":"Emerging fungal infections: New species, new names, and antifungal resistance","volume":"68","author":"Wiederhold","year":"2022","journal-title":"Clin. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12281-021-00419-5","article-title":"Investigational agents for the treatment of resistant yeasts and molds","volume":"15","author":"Seiler","year":"2021","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccm.2017.04.012","article-title":"Allergic and Noninvasive Infectious Pulmonary Aspergillosis Syndromes","volume":"38","author":"Muldoon","year":"2017","journal-title":"Clin. Chest Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5415\/apallergy.2011.1.3.130","article-title":"Allergic Aspergillus sinusitis and its association with allergic bronchopulmonary aspergillosis","volume":"1","author":"Panjabi","year":"2011","journal-title":"Asia Pac. Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MPH.0b013e3181acd956","article-title":"Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study","volume":"31","author":"Rubio","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: Complexities and solutions","volume":"72","author":"Bassetti","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","article-title":"Aspergillosis: Epidemiology, Diagnosis, and Treatment","volume":"35","author":"Cadena","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus Infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: Pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/QCO.0b013e3283165fd1","article-title":"Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment","volume":"21","author":"Ibrahim","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40200-021-00730-5","article-title":"Diabetes and rhino-orbito-cerebral mucormycosis\u2014A deadly duo","volume":"20","author":"Singh","year":"2021","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2147\/IDR.S356465","article-title":"Fatal mucormycosis post COVID-19 infection in uncontrolled diabetes with misuse of glucocorticoids and antibiotics","volume":"15","author":"Hamed","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/S2666-5247(21)00148-8","article-title":"Mucormycosis: Time to address this deadly fungal infection","volume":"2","author":"Stone","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/myc.13092","article-title":"Risk factors for mortality in patients with pulmonary mucormycosis","volume":"63","author":"Son","year":"2020","journal-title":"Mycoses"},{"key":"ref_19","first-page":"e10726","article-title":"Rhino-orbital mucormycosis associated with COVID-19","volume":"12","author":"Mehta","year":"2020","journal-title":"Cureus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"850581","DOI":"10.3389\/fcimb.2022.850581","article-title":"Recent advances and future directions in the understanding of mucormycosis","volume":"12","author":"Garre","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: An initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","first-page":"24","article-title":"Combination antifungal therapy: Where are we now, and where are we going?","volume":"18","author":"Marr","year":"2004","journal-title":"Oncology"},{"key":"ref_23","unstructured":"Merck and Co., Inc. (2022, September 21). Caspofungin (Approved Product Labeling), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206110lbl.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e02119-18","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: A\u2009global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-021-00376-x","article-title":"Pharmacokinetics and Pharmacodynamics of Ibrexafungerp","volume":"22","author":"McCarthy","year":"2022","journal-title":"Drugs R D"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e02068-16","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_31","unstructured":"SCYNEXIS, Inc. (2022, September 21). Ibrexafungerp (Approved Product Labeling), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214900s000lbl.pdf."},{"key":"ref_32","unstructured":"Murphy, G., Darpo, B., Marbury, T., Hyman, M., and Angulo, D. Lack of an effect of SCY-078 a novel antifungal agent on QTc interval in healthy subjects. Abstract 172, Proceedings of the ASM Microbe, New Orleans, LA, USA, 1\u20135 June 2017, SCYNEXIS, Inc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.46.9.3001-3012.2002","article-title":"The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro","volume":"46","author":"Bowman","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e00244-18","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates","volume":"58","author":"Paderu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","unstructured":"Ghannoum, M., Long, L., Sherif, R., Abidi, F.Z., Borroto-Esoda, K., Barat, S., and Wiederhold, N. (2020, January 18). Determination of antifungal activity of SCY-078, a novel glucan synthase inhibitor, against a broad panel of rare pathogenic fungi. Proceedings of the ASM Microbe, Chicago, IL, USA."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e02429-19","DOI":"10.1128\/AAC.02429-19","article-title":"Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1\u21923)-\u03b2-D-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","unstructured":"Jagadeesan, V., Driscoll, E., and Hao, B. (2019, January 20\u201324). In Vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients. Proceedings of the ASM Microbe 2019, San Francisco, CA, USA."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Rivero-Menendez, O., Soto-Debran, J.C., Cuenca-Estrella, M., and Alastruey-Izquierdo, A. (2021). In Vitro Activity of ibrexafungerp against a collection of clinical isolates of Aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies. J. Fungi, 7.","DOI":"10.3390\/jof7030232"},{"key":"ref_43","unstructured":"CLSI (2010). Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi, Clinical and Laboratory Standards Institute. [1st ed.]. CLSI Guideline M51."},{"key":"ref_44","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2022). Eucast Definitive Document E.Def 9.4 Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds, European Committee on Antimicrobial Susceptibility Testing."},{"key":"ref_45","unstructured":"Rautemaa-Richardson, R., Bazaz, R., and Cornely, O.A. (2021, January 18). Outcomes of Oral Ibrexafungerp by Pathogen from two open-label studies of patients with serious fungal infections (FURI and CARES). Proceedings of the 10th Trends in Medical Mycology, Aberdeen, UK."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1207","article-title":"SCY-078 demonstrates significant antifungal activity in a murine model of invasive aspergillosis","volume":"4","author":"Barat","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_47","unstructured":"Petraitis, V., Kavaliauskas, P., and Planciuniene, R. (2018, January 6). In vitro activity of ibrexafungerp in combination with isavuconazole or amphotericin B against medically important molds. Proceedings of the ASM Microbe 2018, Atlanta, GA, USA."},{"key":"ref_48","unstructured":"Gebremariam, T., Alkhazraji, S., and Gu, Y. (2022, January 23). Efficacy assessment of ibrexafungerp in the neutropenic mouse model of pulmonary mucormycosis. Proceedings of the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Lisbon, Portugal."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/11\/1121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:15Z","timestamp":1760144535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/11\/1121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jof8111121"],"URL":"https:\/\/doi.org\/10.3390\/jof8111121","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}